UK-based medical eye drop maker Exonate has raised £1.5m ($1.8m) in funding from investors including Martlet, the investment arm of aerospace and property group Marshall of Cambridge.
Angel CoFund, Uniseed, University of Bristol Enterprise Fund, Wren Capital, O2h Ventures and several undisclosed angel investors also took part in the round, which increased the total raised by the company to just over $11m.
Exonate is developing eye drops to treat retinal neovascular diseases, a range of eye diseases that affect the blood vessels in the eye and result in blindness. The cash will be used to accelerate the development of its lead product.
Martlet, Uniseed, University of Bristol Enterprise Fund, Wren Capital and O2h Ventures had previously contributed to a $1.9m round for the company in 2016. It also received a $5.6m grant from Wellcome Trust in 2017.